Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12379.165 | 0.6076 | -0.5085 | 0.3550 | |
| MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12379.165 | 0.5028 | -0.7116 | 0.3550 | |
| MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12379.165 | 0.3157 | -0.9223 | 0.3550 | |
| MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12379.165 | 0.0149 | -1.0000 | 0.3550 | |
| MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12379.165 | 0.0063 | -1.0000 | 0.3550 | |
| MDA-MB-415 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12333.165 | 0.9032 | 0.6976 | 0.6207 | |
| MDA-MB-415 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12333.165 | 0.8841 | 0.6399 | 0.6207 | |
| MDA-MB-415 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12333.165 | 0.9317 | 0.7846 | 0.6207 | |
| MDA-MB-415 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12333.165 | 0.9774 | 0.9278 | 0.6207 | |
| MDA-MB-415 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12333.165 | 0.8529 | 0.5477 | 0.6207 | |
| MDA-MB-415 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12333.165 | 0.9171 | 0.7397 | 0.6207 | |
| MDA-MB-415 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12333.165 | 0.5564 | -0.2222 | 0.6207 | |
| MDA-MB-415 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12333.165 | 0.0182 | -0.9969 | 0.6207 | |
| MDA-MB-415 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12333.165 | 0.0099 | -0.9988 | 0.6207 | |
| MDA-MB-453 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12414.165 | 1.0537 | 1.0857 | 1.2459 | |
| MDA-MB-453 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12414.165 | 0.9791 | 0.9664 | 1.2459 | |
| MDA-MB-453 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12414.165 | 0.9702 | 0.9520 | 1.2459 | |
| MDA-MB-453 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12414.165 | 0.8480 | 0.7521 | 1.2459 | |
| MDA-MB-453 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12414.165 | 0.6076 | 0.3407 | 1.2459 | |
| MDA-MB-453 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12414.165 | 0.5294 | 0.2005 | 1.2459 | |
| MDA-MB-453 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12414.165 | 0.3013 | -0.2364 | 1.2459 | |
| MDA-MB-453 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12414.165 | 0.0131 | -0.9383 | 1.2459 | |
| MDA-MB-453 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12414.165 | 0.0088 | -0.9554 | 1.2459 | |
| MX1 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12220.158 | 1.0179 | 1.0843 | 0.4308 | |
| MX1 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12220.158 | 1.0883 | 1.4339 | 0.4308 |